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The most critical performance indicator for medical laboratories is the delivery of accurate test
results. In any laboratory, there is always the possibility that random or systematic errors may
occur and place human health and welfare at risk. Laboratory quality assurance programmes
continue to drive improvements in analytical accuracy. The most rigorously scrutinised data on
laboratory errors, which come from transfusion medicine, reveal that the incidence of analytical
errors has fallen to levels where most of the residual risk is now found in preanalytical links in the
chain from patient to result, particularly activities associated with ordering of tests and sample
collection. This insight is important for genetic testing because, like pretransfusion testing of
patients with unknown blood groups, a substantial proportion of genotyping results cannot be
immediately veriﬁed. An increasing number of clinical decisions, associated personal and social
choices, and legal outcomes are now inﬂuenced by genetic test results in the absence of other
conﬁrmatory data. An incorrect test result may lead to unnecessary and irreversible interventions,
which may in themselves have associated risks for the patient, inaccurate risk assessment
regarding the disease, missed opportunities for disease prevention or even wrongful conviction in
a court of law. Unfortunately, there is limited information available about the risk of preanalytical
errors associated with, and few published guidelines regarding, sample collection for genetic
testing. The growing number and range of important decisions made on the basis of genetic
ﬁndings warrant a reappraisal of current standards to minimise risks in genetic testing.
Errors are an established, unwelcome
feature in all areas of healthcare.
1 Erroneous
test results are widespread
2 and are a recog-
nised cause of iatrogenic harm. Incorrect
genetic test results take the issue further.
Besides introducing risks of unnecessary and
irreversible interventions for those being
tested, they may also lead to missed
opportunities for disease prevention among
relatives. With genetics emerging as a
substantial discipline within pathology and
laboratory medicine, there is a responsibility
now to reassess current standards for
minimising risks of error in the ﬁeld.
As with all pathology investigations,
errors may occur at any point in the
genetic test processing chain from test
selection by the clinician to clinical deci-
sions based on the result.
3 Although the
iterative improvements in proﬁciency
testing by molecular genetic testing labo-
ratories have been encouraging,
45they are
also a reminder that genetic testing is not
immune from the usual risks of error.
RISKS ASSOCIATED WITH GENETIC
TESTING
Testing for medically signiﬁcant genetic
variants is growing rapidly, although it is
still a small component of medical testing
overall. In the UK in 2005e2006, genetic
tests accounted for <0.1% of all labora-
tory investigations.
6 Compared with their
working familiarity with most pathology
investigations, many clinicians still have
little experience of testing for inherited or
de novo genomic variants.
As well as the usual challenges associ-
ated with bringing new technologies into
healthcare, there are further issues associ-
ated with genetic investigations to
consider. Genetic ﬁndings may aid the task
of assessing clinical symptoms. They may
also conﬁrm a diagnosis long before the
onset of symptoms in an individual
patient. This is especially the case for
inherited disorders with readily identiﬁable
biomarkers. For example, serum cholesterol
testing of relatives at risk of familial
hypercholesterolaemia has long been
known to reﬁne or resolve genetic risks
identiﬁed by family history. The advent of
genetic testing for this disorder in families
for whom the causal mutation has been
identiﬁed has led to improved diagnostic
accuracy and simpliﬁed the process of risk
assessment among relatives.
7
Genetic testing is increasingly requested
for healthy people identiﬁed by family
history as being at high risk of having
inherited a mutation predisposing to
a serious adult-onset autosomal dominant
monogenic disorder. Many of these
conditions have no associated subclinical
manifestations. Referred to as predictive,
presymptomatic or predisposition testing,
this category of testing is distinguished by
absence of corroborating clinical or other
conﬁrmatory data. This scenario is not
unique to late-onset dominant disorders
and is often seen in other areas of genetic
testing including prenatal, preimplanta-
tion genetic diagnosis, and carrier testing
for autosomal and X linked recessive
disorders. It is also a prominent feature of
‘personalised medicine’,
8 where geno-
typing is used to predict responses to, or
side effects from, drugs.
Corroboration of evidence is an impor-
tant aspect of clinical care. For example,
a normal chest radiograph from a patient
with severe congestive cardiac failure
would normally prompt a check to ensure
the correct image is being viewed. Many
clinical measurements are corroborated by
repeat measurements. The measurement
of blood pressure, for example, can iden-
tify patients at increased risk of stroke.
Although no other clinical features may
be available to corroborate the result,
repeated measurements over time provide
a background in which outlying or
incongruent ﬁndings can be evaluated.
Now, consider the case of testing a
DNA sample from a young woman for
a BRCA1 mutation, which was previously
identiﬁed in her mother, who has a strong
family history of early onset breast cancer.
The investigation will yield a result that is
qualitatively different from the outputs of
most clinical investigations. The woman’s
family history alone will have identiﬁed
her as having a 1 in 2 risk of inheriting the
mutation and, in contrast to many
medical test results, the outcome is binary.
The mutation is either present, in which
case she has a high lifetime risk of breast
and ovarian cancer, or absent, with her
cancer risk returning to the background
population level for women of her age.
Unless veriﬁed by replicate testing, there
are usually no further opportunities to
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Viewpointcorroborate the ﬁnding. Furthermore, the
test result and any associated clinical or
psychosocial sequelae are very likely to
remain unchallenged over a lifetime, and
possibly beyond into the next generation.
In this setting, the risk of error in genetic
testing is not merely academic. Many
genetic testing services have their own
anecdotes and, with permission from the
patient involved, we include an example
from our own experience (see case study).
The case demonstrates that genetic
testing errors can have wide ranging and
lasting sequelae. For example, the fact our
patient did not develop thyroid cancer
could well have been erroneously attrib-
uted in the future to the ‘success’ of his
thyroidectomy, when the real reason was
his risk was negligible in the ﬁrst place.
Although the consequences of a genetic
testing error can have no discernible effect,
particularly if the error remains unde-
tected, a range of outcomes is possible,
including occasional severe harm or
avoidable death.
SOURCES AND FREQUENCY OF GENETIC
TESTING ERRORS
The error we reported was shown to have
occurred during the analytical phase of
testing. However, it could just as easily have
occurred before the sample arrived in the
laboratory or postanalysis. Analytical errors
have been the prime focus of molecular
genetic quality assurance (QA) programmes
developed by professional bodies in the
USA, Europe and Australasia.
9e13 While the
success of these programmes is well
documented, most preanalytical risks,
particularly those associated with the
ordering of tests and sample collection, are
beyond their scope.
There are very few published reports
about the incidence of errors in genetic
testing. One report documented 1.7 errors
per 1000 investigations (excluding errors
in test selection and interpretation).
14
Errors were equally divided between
preanalytical (sample collection and
handling) and analytical phases. A useful
insight from this audit is that the reported
error rate is in the same range as those
reported in other types of medical
testing.
15 In fact, the occult nature of an
erroneous predictive genetic test result, as
illustrated in the case study, demonstrates
that estimates of the prevalence of adverse
consequences associated with predictive
testing are best derived from independent
corroborating data. However, these data
can only come from resampling and
retesting and, as far as we are aware, they
are scanty and anecdotal.
INSIGHTS FROM OTHER AREAS OF
LABORATORY MEDICINE
In contrast to the likelihood that a propor-
tion of genetic testing errors will remain
undetected, errors associated with allogenic
blood transfusion or tissue transplantation
are rapidly unmasked. Life-threatening
immune reactions to mismatched red cell
and tissue immunotypes have focused
attention on the incidence and sources of
errors, and also on strengthening risk
minimisation strategies.
Studies of pretransfusion testing report
that 0.5e0.8 sample tubes per 1000 contain
blood from someone other than the iden-
tiﬁed patient, often referred to as ‘wrong
blood in the tube’ (WBIT).
16 17 They also
reveal other risks, including incomplete
labelling in approximately 11 samples per
1000.
16 18 Such labelling has been shown to
result in a 40-fold increased risk of sample
errors compared with the risk associated
with properly labelled samples.
19
There are no comparable data for genetic
testing. It is important to recognise,
however, that current reported pretrans-
fusion error rates are likely to be lower
than those prevailing in the era before
there was heightened emphasis on risk
minimisation strategies.
20 It is possible
that the situation with genetic testing
may be more hazardous as there are
additional known risks associated with
sample collection. These include labelling
of samples collected from interventional
procedures,
21 such as amniotic ﬂuid,
chorionic villus and fetal blood sampling,
from patients in delivery rooms
22 and
synchronously from relatives.
23
Analytical error rates in pretransfusion
testing have now fallen to levels where
most residual mistakes occur in preanalyt-
ical phases, particularly those associated
with blood sample collection and labelling.
Thesametrendiswelldocumentedinother
general laboratory arenas.
24 25 It is notable
that a range of error-prone preanalytical
tasksareoftencompletedbypeoplebeyond
the jurisdiction of laboratories, including
referring clinicians, clients and carers as
well as workers contributing to data entry,
specimen collection and transport.
RISKS OF PREANALYTICAL ERRORS IN
GENETIC TESTING
Acknowledgement of risks of preanalytical
errors, particularly sample mislabelling,
raises the question whether the safety of
patients undergoing genetic testing is
adequately protected by the current scope
of genetic testing QA programmes.
The prospect of a mislabelled sample
destined for genetic testing highlights an
additional important risk associated with
an adverse outcome. Medical testing is
generally prompted by a patient’s history
or symptoms indicating an increased prior
probability of an underlying disease
process. In the case of predictive genetic
testing, the investigation is prompted by
a family history indicating a high risk of
predisposition to future illness from an
inherited gene mutation. The prior risk of
abnormalityinamislabelledsampledeﬁnes
the likelihood that a result will differ from
thepatient’struestatus.Forexample,if1in
20 samples from a patient cohort have
abnormal test results, then analyses of
swapped samples will yield correct results
Case study
A 40-year-old male patient was diagnosed with an extra-adrenal paraganglioma. Family
history revealed a fourth degree relative who presented with medullary thyroid cancer at
25 years of age. Early-onset medullary thyroid cancer is the hallmark of multiple endocrine
neoplasia type 2, which is an autosomal dominant disorder due to mutations in the RET
gene. Some mutation carriers remain healthy, but their risk of developing thyroid cancer is
high. RET mutations can also be associated with paragangliomas. The patient was tested
for a heritable RET mutation by an accredited laboratory, and a well-recognised pathogenic
mutation was identiﬁed. He proceeded to have a prophylactic thyroidectomy, which is the
recommended management for mutation carriers. The patient’s unaffected children
subsequently had predictive genetic testing and none was identiﬁed with the mutation. The
relative with thyroid cancer was eventually reviewed and testing demonstrated that
she did not have our patient’s RET mutation. Instead, a different mutation was identiﬁed
in the same gene. Repeat sample collection and analysis demonstrated that the RET
mutation originally identiﬁed in the index patient was a laboratory artefact. The revised
result eliminated the earlier justiﬁcation for his prophylactic thyroidectomy and also for the
predictive genetic testing of his children. He was subsequently shown to have a heritable
mutation in the SDHD gene. Although the amended diagnosis also has familial implications,
his children are now disenchanted and have declined further involvement with the clinic.
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Viewpointfor both patients more than 90% of the
time. Alternatively, an inadvertent switch
of samples from individuals in whom the
prior risk of abnormality is 1 in 2, which is
the case among siblings at risk of having
inherited a mutation from an affected
parent, will yield correct results for both
individuals only 50% of the time.
In the context of a family history of
disease, the elevated prior probability of
having inherited the disease-causing
mutation also raises the risk of harm
arising from sampling errors. This risk is
compounded by the earlier mentioned
evidence of increased risk of sample
mislabelling associated with synchronous
sample collection from relatives.
23
Although some indication of the likely
background error rate associated with
predictive genetic testing would be useful,
any estimate will inevitably be the average
of numerous random and systematic error
rates, all of which will also be inevitably
subject to regional variation and changes
over time. Notwithstanding these limita-
tions, it is apparent that the current ad
hoc approach to minimising preanalytical
risks associated with genetic testing,
particularly the risk of sampling errors, is
a patient safety issue that requires
research attention. Meanwhile, it is
important that those involved in this area
of medicine consider all potential weak-
nesses in the total testing process, and
then avail themselves of the full range of
available risk minimisation strategies.
GRADIENT OF RISK MANAGEMENT
STRATEGIES
Experience from transfusion and trans-
plantation medicine provides guidance on
risk minimisation strategies for genetic
testing. These services have implemented
measures over many years to decrease the
incidence of sampling errors. Importantly,
both these services reject the baseline
standard of analysing single specimens
that fulﬁl minimum labelling criteria, such
as concordance of two person-speciﬁc
identiﬁers on the sample tube and
accompanying request form.
26
To ensure against transfusing the wrong
blood into a patient, transfusion services
use a range of strategies which, in general
terms, have focused on strengthening the
chain of custody procedures in lieu of
analysis of a second independently drawn
sample. Measures include requiring
a second person to conﬁrm concordance of
patient identity, request form and sample;
avoiding prelabelled tubes; appointing
safety ofﬁcers to oversee training and
processes; and using electronic patient
identiﬁcation systems. A multicentre
international survey of 650000 samples
reported in 2003 that 6.1 samples per 1000
were mislabelled
16 and a WBITrate of 0.5
samples per 1000, despite almost all
participating laboratories having written
policies on sample collection and
labelling.
27 The Division of Transfusion
Medicine at the University of California,
Los Angeles, as a result of a 17-year policy
of requiring two independent samples for
blood typing before issuing type-speciﬁc
blood for non-group-O patients, reported
a very similar mislabelling rate of 0.44
samples per 1000.
22 In keeping with the
policy of the University of California, Los
Angeles, the World Marrow Donor Asso-
ciation also established guidelines recom-
mending conﬁrmatory tissue typing on
duplicate samples from potential donors
and recipients before transplantation.
28
The policy of conﬁrmatory testing of a
second independent blood sample for
patients without a historical record
corroborating an ABO typing result from
a single sample has since been adopted by
more transfusion services and now
extends to approximately 20% of US
laboratory and hospital practices.
18
CURRENT SAMPLE VERIFICATION
PROTOCOLS IN GENETIC TESTING
Although there has been a long-standing
focus on reducing the risk of sampling
errors associated with transfusion and
transplantation, most contemporary
reports
29 30 and documents on genetic
testing developed by regulatory and
professional bodies
31e38 have primarily
addressed strengthening laboratory QA.
With some notable exceptions,
39 40 few
have argued in favour of adopting a more
patient-centric approach to risk mini-
misation, including addressing risks asso-
ciated with sample collection. A survey of
directors of 17 medical genetic laboratories
in Australia and New Zealand in 2005,
41
before sampling risk minimisation guide-
lines were implemented, revealed a range
of approaches. In lieu of duplicate
sampling, some laboratories split samples
for predictive testing into two tubes
immediately on arrival, and then arranged
independent replicate analyses. However,
most laboratories accepted single unsigned
samples for predictive genetic testing after
ensuring concordance of patient identi-
fying details on request forms and
samples. Subsequently, an Australian
laboratory accreditation guideline, which
is not obligatory, was issued in 2006
recommending that predictive genetic
tests be conducted on duplicate samples.
42
VERIFYING GENETIC TEST RESULTS
Genetic testing is increasingly used to
resolve clinical uncertainty in a diverse
array of medical scenarios. Many scenarios
offer opportunities to corroborate genetic
test ﬁndings. For example, a test report
that a child has mutations in both CFTR
genes may be veriﬁed by a pre-existing
clinical diagnosis of cystic ﬁbrosis (an
autosomal recessive disorder caused by
CFTR mutations), by ﬁnding an elevated
sweat chloride concentration (a speciﬁc
biochemical feature of cystic ﬁbrosis) or by
demonstrating that the parents are carriers
of the child’s mutations. As another
example, an array genomic scanning result
in a sample from a 3-year-old child with
autism might unexpectedly demonstrate
a genomic deletion involving the TP53
gene. The ﬁnding may prompt a discovery
of a previously unrecognised family
history indicative of Li Fraumini
syndrome. However, as the case study we
present illustrates, the family history may
be misleading, inconclusive or absent, in
which case duplicate sampling would avert
the risk of arranging inappropriate predic-
tive genetic tests for relatives. The number
of conﬁrmatory options already available
demonstrate the usefulness of an informed
and practical approach to risk mini-
misation in genetic testing, particularly in
the absence of peer reviewed data and QA
programmes that focus on the quality of
all links in the chain from patient to result.
RISK MINIMISATION STRATEGIES FOR
GENETIC TESTING
There is at the very least an ethical
imperative that any genetic test ﬁnding
with the potential to inﬂuence signiﬁcant
clinical, personal or social decisions should
prompt consideration of all associated
risks, including the risk of an erroneous
result. A recent report to the Victorian
Department of Justice
43 offers an illumi-
nating insight into contemporary societal
views on the strength of DNA evidence.
An inquiry into the wrongful conviction
of a man for rape in July 2008 identiﬁed
that the conviction had hinged on DNA
evidence derived from a single sample. At
the time of the man’s conviction, it had
not been appreciated that the sample had
been collected in the same unit as forensic
samples secured by the same doctor 30 h
earlier from another woman, with whom,
it was undisputed, the man had had prior
sexual contact. A former judge who
conducted the review warned:
. the DNA evidence had been perceived as
being so powerful by all involved in the
J Clin Pathol May 2012 Vol 65 No 5 391
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our system of criminal justice depends to
minimise the risk of a miscarriage of
justice, operated effectively at any stage
until a matter of weeks before [the man’s]
appeal was expected to be heard.
The fact an innocent man spent time in
jail as a convicted rapist on the basis of an
uncorroborated genetic identity test result
is a sobering reminder of the extent of
potential ‘fall out’ when things go wrong
in genetic testing. Clearly, such errors are
not solely a concern for medical providers.
Sensibly, the importance of corroborating
a genetic test result will vary as will the
best ways of achieving veriﬁcation. Ideally,
consideration should be made of the likely
risk of error; the seriousness and frequency
of any possible adverse consequences; and
the range, effectiveness and total cost of
available risk minimisation strategies.
Examination of legal and ﬁnancial risks for
those who are professionally accountable
may also need to be included in the cost
analysis.
There is a strong argument now that
healthcare practitioners involved in
requesting or performing genetic tests
which have potentially fatal outcomes
associated with sampling errors should
recognise that the baseline standard of
analysing single specimens fulﬁlling
minimum labelling criteria represents
inadequate risk minimisation for the
patient.
44 45 The full scope of potentially
fatal outcomes must also be considered,
including any risk of future fatalities
linked to missed opportunities for disease
prevention among relatives. Further, given
the range of deleterious non-fatal
outcomes associated with genetic testing,
there is a case for extending this recom-
mendation to incorporate signiﬁcant clin-
ical, personal, social or legal decisions that
may be directed by a genotype ﬁnding.
There are, however, several additional
measures to consider in relation to
genetic testing. For example, the option of
routine replicate testing on independent
samples has long been regarded as inap-
propriate for prenatal genetic diagnosis,
particularly if the invasive procedure
required to obtain a second sample has
attendant potentially serious risks, either
forthemotheror forthefetus.Fortunately,
in this arena, simultaneous testing of non-
disease associated genetic polymorphisms
in fetal and parental DNA samples is an
increasingly available option to detect
sample switching, and also to assess for
possible maternal cell contamination.
46
It is worth noting that in other arenas,
such as predictive genetic testing for
serious late-onset dominant disorders,
including familial cancers, late-onset
neurodegenerative disorders and heredi-
tary arrhythmia syndromes, some profes-
sional organisations
47 48 have issued
guidelines recommending replicate testing.
When considering the option of replicate
testing, some practitioners may contem-
plate arranging the test in a second labo-
ratory to provide additional protection
against unrecognised laboratory-speciﬁc
risks of systematic error. This opportunity,
however, would not be available for
genetic tests that are currently monopo-
lised through patents or licensing.
With ongoing genetic advances, the
issue of risk minimisation in relation to
genetic testing is now extending into
mainstream medical practice. Pharmaco-
genomic testing has a growing role in
guiding therapeutic decisions, including
management of hepatitis C virus infection,
which is the most common bloodborne
infection in the USA.
49 Until now, there
has been little commentary about whether
there is a need to strengthen the quality of
preanalytical and postanalytical phases
associated with pharmacogenomic testing,
particularly in the boundary areas linking
clinical and laboratory medicine.
While risk minimisation strategies
should be tailored to individual clinical
scenarios, cost-effectiveness is an impor-
tant consideration. For example, if we
accept that a single sample is appropriate
for prenatal testing of fetal tissue, there are
few published recommendations regarding
the minimum labelling and chain of
custodyrequirementsotherthaninrelation
to paternity testing. What impact would
strengthened risk minimisation measures
have on the cost of delivering prenatal
testing? And would the extra cost be
acceptable to those paying for the service?
In the absence of widely accepted
professional guidelines, QA programmes or
peer reviewed data for genetic test
sampling, the decision to implement
a more stringent sample protocol is ulti-
mately directed locally based on what is
known about the clinical risks involved.
Venesectionists, laboratory scientists and
pathologists are not necessarily aware of
these details. The ultimate responsibility
for individual patient safety is vested in the
clinician requesting the investigation. On
the other hand, laboratory-based practi-
tioners are well placed to remind referring
clinicians of sampling recommendations.
CONCLUSION
The goal of a clinician is to provide the
patient with an accurate diagnosis, prog-
nosis and therapeutic options, including in
relation to diseases for which genetic tests
are available. Similarly, the goal of
a medical laboratory is to provide the right
result for the right patient in a timely
fashion every time. Alexander Pope wrote
in An Essay on Criticism that ‘To err is
human.’. Three hundred years later, his
message is still potent. All arenas of
human endeavour are at risk of human
error, and the emerging discipline of
genetic testing is not immune. Errors will
occur here, as they do in other areas of
laboratory testing, and medicine in
general. It is of little comfort that sample
errors, such as WBIT, are likely to be
more common than reports of adverse
incidents.
Like the proverbial elephant in the
room, we know the errors are present but
we hesitate to talk about them. The issue
must be addressed, however, because
errors in genetic testing have the potential
to prompt clinical decisions with a high
risk of attendant harm. They may also
direct important life choices for those
being tested, with ramiﬁcations that may
inﬂuence human health and welfare at all
developmental stages. Some errors will
invariably lead to outcomes over which
the person being tested will have no
control, such as wrongful conviction in
a court of law. Errors in genetic testing
may also waste the increasingly scarce
health dollars, and place individual
healthcare practitioners at professional,
legal and ﬁnancial risk. It is now time for
the profession to consider the full range of
errors that are possible along the genetic
test processing chain from patient to
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misation strategies. Until such data are
available, individual healthcare practi-
tioners involved in genetic testing should
consider the associated possible risks to
patient health and welfare, and look
beyond the baseline standard of testing
a single sample.
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